GUTS Share Price Performance
US$2.16
0.15 (7.20%)
71.0% undervalued intrinsic discount
US$7.44
Fair Value
Price US$2.16
AnalystConsensusTarget US$7.44
Fair ValueUS$7.44
Share Pricen/a
Fractyl Health, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
GUTS Community Narratives
AN
Fair Value US$7.44 71.0% undervalued intrinsic discount
Durable Obesity Therapies And GLP 1 Trends Will Drive Long Term Upside
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Durable Obesity Therapies And GLP 1 Trends Will Drive Long Term Upside
Catalysts About Fractyl Health Fractyl Health is developing minimally invasive, procedure based and genetic therapies that target root causes of obesity and type 2 diabetes to deliver durable metabolic control. What are the underlying business or industry changes driving this perspective?Read more
4
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$7.44
71.0% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
3.07k% p.a.
Profit Margin
0.13%
Future PE
127.62x
Price in 2028
US$0.05
Trending Discussion
Recently Updated Narratives
AN
Durable Obesity Therapies And GLP 1 Trends Will Drive Long Term Upside
Fair Value: US$7.44 71.0% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Fractyl Health, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.89
- 100.00%
- -4,073,233.33%
- -968.2%
About GUTS
- Founded
- 2010
- Employees
- 101
- CEO
- WebsiteView website
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
